Medicare AdvantageCoverageMedium impact
MA08.188, Linvoseltamab-gcpt (Lynozyfic)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
MA08.188 is a new Medicare Advantage policy for Linvoseltamab-gcpt (Lynozyfic), a pharmacy benefit drug effective October 20, 2025. The billing team must implement this policy in their systems to ensure proper coverage determination, prior authorization requirements, and claims processing for this new medication.
Action Required
By October 20, 2025: Pharmacy and billing teams must obtain the complete policy text from the source URL to identify specific billing codes (J-codes for drug administration), prior authorization requirements, and coverage criteria for Linvoseltamab-gcpt. Update billing software and pharmacy systems to reflect any prior authorization workflows, coverage limitations, and correct HCPCS J-codes. Alert providers and pharmacy staff of the new coverage policy. NOTE: The policy content summary provided does not include specific billing codes or detailed requirements; obtain full policy details immediately to implement properly. Claims submitted without adherence to this new policy may be denied.